Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Cost of Revenue (2018 - 2025)

Exagen (XGN) has disclosed Cost of Revenue for 8 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 43.4% year-over-year to $7.4 million, compared with a TTM value of $27.8 million through Dec 2025, up 23.29%, and an annual FY2025 reading of $27.8 million, up 23.29% over the prior year.
  • Cost of Revenue was $7.4 million for Q4 2025 at Exagen, up from $7.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $7.4 million in Q4 2025 and bottomed at $4.7 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $5.9 million, with a median of $5.8 million recorded in 2022.
  • The sharpest move saw Cost of Revenue surged 63.3% in 2021, then dropped 10.92% in 2023.
  • Year by year, Cost of Revenue stood at $4.9 million in 2021, then grew by 27.74% to $6.3 million in 2022, then fell by 10.92% to $5.6 million in 2023, then decreased by 7.86% to $5.2 million in 2024, then skyrocketed by 43.4% to $7.4 million in 2025.
  • Business Quant data shows Cost of Revenue for XGN at $7.4 million in Q4 2025, $7.2 million in Q3 2025, and $6.8 million in Q2 2025.